Insider Selling: Ultragenyx Pharmaceutical (NASDAQ:RARE) EVP Sells $240,289.20 in Stock

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) EVP Erik Harris sold 10,539 shares of the company’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $22.80, for a total transaction of $240,289.20. Following the transaction, the executive vice president owned 89,515 shares in the company, valued at approximately $2,040,942. The trade was a 10.53% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Ultragenyx Pharmaceutical Price Performance

Shares of NASDAQ RARE opened at $21.46 on Friday. The company has a 50-day moving average price of $23.30 and a 200-day moving average price of $29.14. The stock has a market capitalization of $2.07 billion, a P/E ratio of -3.67 and a beta of 0.16. Ultragenyx Pharmaceutical Inc. has a 1 year low of $18.41 and a 1 year high of $42.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings results on Thursday, February 12th. The biopharmaceutical company reported ($1.29) earnings per share for the quarter, missing the consensus estimate of ($1.20) by ($0.09). The business had revenue of $207.28 million during the quarter, compared to the consensus estimate of $199.60 million. Ultragenyx Pharmaceutical had a negative net margin of 85.54% and a negative return on equity of 1,024.42%. Ultragenyx Pharmaceutical’s revenue was up 25.5% compared to the same quarter last year. During the same period in the previous year, the business posted ($1.39) EPS. As a group, equities research analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

Large investors have recently modified their holdings of the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Ultragenyx Pharmaceutical by 14.8% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 232,360 shares of the biopharmaceutical company’s stock worth $8,414,000 after purchasing an additional 29,984 shares during the period. Envestnet Asset Management Inc. increased its position in Ultragenyx Pharmaceutical by 6.0% in the second quarter. Envestnet Asset Management Inc. now owns 29,956 shares of the biopharmaceutical company’s stock worth $1,089,000 after buying an additional 1,698 shares during the last quarter. Teacher Retirement System of Texas raised its stake in shares of Ultragenyx Pharmaceutical by 1.8% in the second quarter. Teacher Retirement System of Texas now owns 22,773 shares of the biopharmaceutical company’s stock valued at $828,000 after buying an additional 404 shares during the period. Amalgamated Bank lifted its position in shares of Ultragenyx Pharmaceutical by 9.7% during the 2nd quarter. Amalgamated Bank now owns 6,757 shares of the biopharmaceutical company’s stock valued at $246,000 after buying an additional 598 shares during the last quarter. Finally, EFG Asset Management North America Corp. grew its stake in shares of Ultragenyx Pharmaceutical by 10.5% during the 2nd quarter. EFG Asset Management North America Corp. now owns 135,850 shares of the biopharmaceutical company’s stock worth $4,939,000 after acquiring an additional 12,908 shares during the period. Hedge funds and other institutional investors own 97.67% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on RARE shares. Leerink Partners lowered their price target on Ultragenyx Pharmaceutical from $80.00 to $70.00 and set an “outperform” rating for the company in a research report on Tuesday, December 30th. Canaccord Genuity Group reduced their target price on shares of Ultragenyx Pharmaceutical from $128.00 to $79.00 and set a “buy” rating for the company in a research note on Wednesday, February 18th. Bank of America lowered their target price on shares of Ultragenyx Pharmaceutical from $72.00 to $58.00 and set a “buy” rating for the company in a report on Friday, January 2nd. Barclays cut their price target on shares of Ultragenyx Pharmaceutical from $81.00 to $50.00 and set an “overweight” rating on the stock in a report on Monday, November 24th. Finally, HC Wainwright decreased their price objective on shares of Ultragenyx Pharmaceutical from $60.00 to $50.00 and set a “buy” rating for the company in a research note on Tuesday, February 17th. Sixteen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Ultragenyx Pharmaceutical has a consensus rating of “Moderate Buy” and an average price target of $68.29.

Key Ultragenyx Pharmaceutical News

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Neutral Sentiment: Regulatory/procedural deadline — multiple firms are reminding eligible purchasers of the April 6, 2026 lead plaintiff deadline for the class action; this is a procedural notice but focuses attention on potential litigation exposure. ROSEN Deadline Notice
• Negative Sentiment: Class action filings and widespread solicitations — multiple law firms (Pomerantz, Robbins Geller, ClaimsFiler, Bronstein Gewirtz & others) have circulated notices and at least one suit has been filed alleging misstatements/omissions tied to setrusumab results; that raises potential legal and financial risk. Pomerantz Notice
• Negative Sentiment: Legal overhang amplified by media/legal alerts — additional reminders from ClaimsFiler, Robbins LLP, Furuqi & Furuqi and others increase publicity around the suit and the potential damages/settlement risk. ClaimsFiler Alert
• Negative Sentiment: Prior clinical setback cited by plaintiff counsel — Levi & Korsinsky highlights the company’s >40% decline after a Phase III setrusumab failure disclosure, framing the litigation narrative and reinforcing investor concern about program and disclosure risk. Levi & Korsinsky Alert
• Negative Sentiment: Insider selling — CFO Howard Horn disclosed multiple recent sales (including March 3 sale of 1,635 shares), feeding short‑term sentiment pressure even if not necessarily signaling company fundamentals. Insider Trades Report

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.